Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.31 |
| ▸ | ITGAV | P06756 | 7/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557910 | 0.86 | PLAU (0.33) | ITGB3ITGA2B | |
| SCHEMBL4459041 | 0.81 | ITGB3 (0.36) | ITGB3ITGAVITGA2B | |
| SCHEMBL4462974 | 0.77 | ITGB3 (0.38) | ITGB3ITGAVITGA2BADAMTS4ALDH1A1 | |
| SCHEMBL2243219 | 0.67 | ADAMTS4 (0.37) | ITGB3ITGAVITGA2BADAMTS4ITGB1 | |
| SCHEMBL3747259 | 0.65 | F10 (0.58) | — | |
| SCHEMBL4450993 | 0.65 | ADAMTS4 (0.44) | ADAMTS4ALDH1A1MAPT | |
| SCHEMBL16143908 | 0.62 | — | — | |
| SCHEMBL19639375 | 0.61 | CYP2D6 (0.51) | ALDH1A1MAPT | |
| SCHEMBL2241632 | 0.61 | PLG (0.42) | CTSSCTSKITGB3ITGAVITGA2B | |
| SCHEMBL13785636 | 0.60 | CYP17A1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538216-B2 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2009-05-26 | — | — | US | disclosed |
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | PLAU, PLAUR, ENPEP | CTSB 406/4885CTSS 479/4885CTSK 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.